New pneumococcal 15-valent conjugate vaccine that includes coverage against serotype 3

Description

In this Product Explainer, Public Health Physician and Infectious Diseases Epidemiologist Prof Paul Van Buynder explains the burden of pneumococcal disease in both children and adult population. He explains why PCV 15 has increased serotype coverage and why improved immunogenicity against serotype 3 is important both from a clinical and public health perspective (5 mins).

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Prof Rodney Baber AM

Prof Rodney Baber AM

MHT For Women With History or Risk of Cancer

Dr Chris Bollen

Dr Chris Bollen

Muscle Health in the Elderly

Prof Brendon Yee

Prof Brendon Yee

GLP-1s For OSA

Dr Andrew Scroop

Dr Andrew Scroop

Oral Corticosteroid Stewardship For Asthma – Why it is Important

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Prof Paul Van Buynder

expert

Prof Paul Van Buynder

Public Health Physician and Infectious Diseases Epidemiologist; Professor, School of Medicine, Griffith University, Queensland

Date published: 25 July 2023